by Swiss Approval | 26 July 2024 | Lung Cancer
Alectinib has been approved by the Swissmedic as a monotherapy for adjuvant treatment in adult patients with ALK-positive stage IB (tumor ≥4cm) to IIIA non-small cell lung cancer after complete tumor resection. The recommended dose is 600 mg twice daily. It is...
by Swiss Approval | 4 July 2024 | Lung Cancer
Durvalumab in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, has received approval from Swissmedic for the treatment of adult patients with resectable NSCLC (tumours ≥4 cm and/or positive...
by EMA Approval | 10 June 2024 | Lung Cancer
The European Commission has granted approval for the use of the tyrosine kinase inhibitor (TKI) alectinib as an adjuvant treatment for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who are at high risk of recurrence following...
by EMA Approval | 7 June 2024 | Lung Cancer
The FDA and the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) have approved or recommended a wave of new drugs that are set to transform cancer treatment. These approvals span across various oncological areas, including...
by FDA Approval | 16 May 2024 | Lung Cancer
On May 16, 2024, the Food and Drug Administration (FDA) gave accelerated approval to Imdelltra (tarlatamab-dlle), developed by Amgen, Inc., for treating extensive stage small cell lung cancer (ES-SCLC) that has progressed despite platinum-based chemotherapy. In a...
